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Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a
substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulation aims
to prevent thrombus extension and reduce the risk of recurrent events, particularly fatal pulmonary embolism. In
EINSTEIN DVT, rivaroxaban was non-inferior to enoxaparin/vitamin K antagonists for the reduction of recurrent VTE,
with a similar safety profile and a net clinical benefit. EINSTEIN EXT investigated patients receiving long-term treatment
in whom there was no clear decision about continuing or stopping anticoagulation; rivaroxaban was superior to
placebo in the reduction of recurrent VTE, showing an acceptable benefit–risk balance. Rivaroxaban has the potential
to replace standard therapy, usually parenteral low molecular weight heparin overlapping with and followed by a
vitamin K antagonist, for the treatment of acute symptomatic DVT and the secondary prevention of VTE. As the use of
rivaroxaban for DVT treatment increases in clinical practice, a fundamental understanding of its clinical benefits in
everyday patient care is essential. XALIA (XArelto for Long-term and Initial Anticoagulation in venous thromboembolism)
is a multicentre, prospective, non-interventional, observational study investigating the effectiveness and safety of a
single-drug approach with rivaroxaban compared with standard therapy in patients with DVT. The study cohort will
include approximately 4800 patients (≥18 years old) with objectively confirmed acute DVT who will be treated for a
period of ≥3 months. The primary outcomes will be the incidence of treatment-emergent adverse events (primarily
major bleeding), symptomatic recurrent venous thromboembolic events and all-cause mortality. Secondary outcomes
include: major cardiovascular events; patient-reported treatment satisfaction and adherence; healthcare resource
utilization; reasons for drug switching or interruption of treatment; and adverse events. XALIA will follow an international
cohort of patients in more than 20 European countries, and others including Israel and Canada. The first patient was
enrolled in June 2012, with results expected in 2015. It is anticipated that XALIA will provide important information on
the treatment of DVT in a heterogeneous, unselected patient population in a real-world setting and provide important
supplementary information to that obtained from the EINSTEIN DVT phase III study.
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Acute venous thromboembolism (VTE), which comprises
deep vein thrombosis (DVT) and pulmonary embolism
(PE), is the third most common cardiovascular disorder
[1]. VTE occurs with an incidence of 1–2 cases per 1000
people in the general population and the risk increases
with age [2,3]. Treatment of VTE involves an initial phase,
in which the key imperative is to prevent thrombus
extension, improve acute symptoms and reduce the
risk of early PE [4]. The current standard treatment
for acute VTE is overlapping anticoagulation with a
parenteral agent (such as low molecular weight heparin
[LMWH]) and a vitamin K antagonist (VKA) [5]. VKAs
may be given over a period of months, years, or even
indefinitely, to reduce the risk of recurrent events.
Guidelines on the duration of anticoagulant therapy for
VTE, including those published by the American College
of Chest Physicians (ACCP), recommend at least 3 months’
treatment after a provoked or unprovoked event [5].
Anticoagulation with LMWH is rapid and effective,
but the need for daily subcutaneous injections can be
challenging. Heparin-induced thrombocytopenia may be
a risk with LMWH use, with an incidence of ≤1% in
medical and postoperative patients [6]. The limitations of
VKAs in routine clinical practice are well documented:
treatment with these agents requires regular monitoring
to ensure patients remain within the therapeutic range
(international normalized ratio 2.0–3.0), and a wide range
of drug–drug and drug–food interactions may influence
therapeutic levels of anticoagulation. Initial adjustment of
VKA dosing in the first weeks of therapy is particularly
challenging and in some cases is not easy to achieve
[7]. Furthermore, the use of a dual-drug approach with
LMWH and VKAs can be both complex and burdensome
for patients and healthcare providers.
Direct oral Factor Xa inhibitors, such as apixaban,
edoxaban and rivaroxaban, and the direct oral thrombin
inhibitor dabigatran, have recently been investigated in
phase III clinical trials for the treatment and secondary
prevention of DVT and PE [8-15]. Rivaroxaban and
apixaban have both been studied as a single-drug
approach, whereas edoxaban and dabigatran employed
an initial course of parenteral heparin therapy before
commencing therapy with the anticoagulant being
investigated. Data show that these agents are effective
and well tolerated; however, it is not known whether
these findings are directly applicable to patients in a
real-world setting. As the use of the direct oral anti-
coagulants in clinical practice increases, a fundamental
understanding of their efficacy and safety in patients with
VTE treated in routine care is essential. XALIA (XArelto
for Long-term and Initial Anticoagulation in venous
thromboembolism) will investigate the effectiveness of a
single-drug approach with rivaroxaban compared withstandard dual-drug therapy with LMWH/VKAs in the
real-world treatment of patients with DVT.
Rivaroxaban
Rivaroxaban is a direct oral Factor Xa inhibitor with a
high oral bioavailability (≥80%) [16] and predictable
pharmacokinetics and pharmacodynamics [17,18]; these
characteristics provide the basis for use of this agent
without the need for routine coagulation monitoring.
The onset of action of rivaroxaban, i.e. its anti-Factor Xa
activity, has been shown to be as fast as that of the
LMWH enoxaparin [19]. Peak plasma concentrations of
rivaroxaban are achieved within 2–4 hours and it has a
mean half-life of approximately 9 hours (5–9 hours in
young individuals and 11–13 hours in the elderly)
[17,18]. Rivaroxaban is associated with few drug–drug
[20-22] or drug–food interactions [23]. However,
rivaroxaban doses of 15 mg and 20 mg should be taken
with food to maintain high oral bioavailability [23].
XALIA is being conducted in response to a request
made by the European Medicines Agency (EMA) to
evaluate rivaroxaban for the treatment of acute DVT
after the completion of the large phase III EINSTEIN
DVT study. The EINSTEIN phase III clinical programme
investigated the use of rivaroxaban as a single-drug ap-
proach in contrast to the current dual-drug paradigm
of enoxaparin/VKAs [8,9]. EINSTEIN DVT was a ran-
domized, open-label, event-driven, non-inferiority trial
that investigated the efficacy and safety of oral rivar-
oxaban (15 mg twice daily for 21 days followed by
20 mg once daily) compared with subcutaneous enox-
aparin (1 mg/kg body weight twice daily for at least
5 days) overlapping with and followed by a VKA
(warfarin or acenocoumarol, started within 48 hours
after randomization), in patients with acute, symptom-
atic, objectively confirmed proximal DVT without PE.
Treatment duration was at the discretion of the attending
physician and was planned for 3, 6 or 12 months [8].
In EINSTEIN DVT, rivaroxaban was shown to be non-
inferior to enoxaparin/VKA for the reduction of recurrent
VTE (Table 1) [8]. Rates of first major or non-major
clinically relevant bleeding (the primary safety outcome)
were similar in patients receiving rivaroxaban compared
with patients receiving enoxaparin/VKA. In addition,
rivaroxaban was associated with a significantly improved
net clinical benefit (defined as the composite of symp-
tomatic, recurrent VTE and major bleeding), compared
with enoxaparin/VKA (Table 1) [8]. The consideration
of patient-reported outcomes is becoming increasingly
important when evaluating the overall effectiveness of
direct oral anticoagulants. It is worth noting that an
EINSTEIN DVT subanalysis showed that rivaroxaban was
associated with improved treatment satisfaction compared
with enoxaparin/VKA therapy in patients with DVT [24].
Table 1 Efficacy and safety outcomes of the phase III EINSTEIN DVT study
Rivaroxaban Enoxaparin/VKA HR (95% CI) P value
Efficacy outcomes (ITT population) (n = 1731) (n = 1718)
Recurrent VTE* (%) 2.1 3.0 0.68 (0.44–1.04) <0.001
Safety outcomes (safety population) (n = 1718) (n = 1711)
First major or non-major clinically relevant bleeding† (%) 8.1 8.1 0.97 (0.76–1.22) 0.77
Major bleeding (%) 0.8 1.2 0.65 (0.33–1.30) 0.21
Non-major clinically relevant bleeding (%) 7.3 7.0
Total mortality (%) 2.2 2.9 0.67 (0.44–1.02) 0.06
Any treatment-emergent adverse event (%) 62.7 63.1
Net clinical benefit 2.9 4.2 0.67 (0.47–0.95) 0.03
(composite of symptomatic, recurrent VTE plus major bleeding, %)
*Primary efficacy outcome; †principal safety outcome.
CI, confidence interval; DVT, deep vein thrombosis; HR, hazard ratio; ITT, intention to treat; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE,
venous thromboembolism.
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reported anticoagulation burden and an increase in
convenience [24]. It would, therefore, be desirable to
confirm the influence of rivaroxaban treatment on patient
lives in routine care.
The EINSTEIN PE study investigated rivaroxaban in
patients with acute, symptomatic PE, and also showed
that it was non-inferior to enoxaparin/VKA, with a
51% reduction in the incidence of major bleeding [9].
The EINSTEIN EXT study investigated rivaroxaban in
patients receiving long-term treatment in whom there
was no clear decision about continuing or stopping
anticoagulation; rivaroxaban was superior to placebo in
the reduction of recurrent VTE, and showed an acceptable
benefit–risk balance [8].
Rivaroxaban is the first direct oral anticoagulant to be
approved for the treatment of DVT and PE and secondary
prevention of VTE in the European Union, US and Canada.
XALIA is a multicentre, prospective, non-interventional,
observational study taking place across more than 20
European countries, and other countries including
Israel and Canada. XALIA will assess whether the
results obtained with rivaroxaban in real-world clinical
practice in patients with objectively confirmed, acute
DVT and an indication to receive anticoagulation for at
least 3 months are consistent with those seen in the phase
III EINSTEIN DVT study.
The main objective of the study is to evaluate the safety
of rivaroxaban in routine clinical practice for the treatment
of acute symptomatic DVT and prevention of recurrent
VTE by examining the incidence of treatment-emergent
adverse events: major bleeding, symptomatic recurrent
venous thromboembolic events and all-cause mortality.
XALIA study design
The study cohort consists of patients with acute DVT
treated with rivaroxaban or current standard therapy(initial treatment with unfractionated heparin, LMWH
or fondaparinux, which may overlap with and be
followed by an oral VKA) for a period of ≥3 months.
The study duration will be 12 months from the final
date of patient enrolment, but the treatment duration
for each patient will be determined solely by the attending
physician and does not depend on the initial intended
treatment duration or the study duration. The first patient
was enrolled in June 2012 and the end of study is expected
in 2015.Administrative organization
Non-interventional post-authorization safety studies are
recommended for review by Ethics Committees, and the
study/sponsor sought approval from an independent Ethics
Committee or Institutional Review Board in all countries
where such procedures were in place.
An external expert scientific Steering Committee will
give support regarding study objectives, study conduct
and analysis. An independent Adjudication Committee
blinded to the treatment group will adjudicate events.
Members of the Steering Committee may also serve
on the Adjudication Committee; however, no sponsor
representatives will serve on the Adjudication Committee.
The study is registered at clinicaltrials.gov (NCT01619007).Centre and patient selection
Recruitment of patients will be conducted by investigators
at selected study centres in Europe and other regions in
which rivaroxaban is approved. Enrolment is planned
for approximately 4800 patients with approximately
equal numbers in each arm. Patients can be enrolled
immediately after a decision about the choice of anti-
coagulant therapy has been made, but no randomization
will be undertaken. Inclusion and exclusion criteria are
summarized in Table 2.
Ageno et al. Thrombosis Journal 2014, 12:16 Page 4 of 7
http://www.thrombosisjournal.com/content/12/1/16Patients who are ≥18 years old, with a diagnosis of
objectively confirmed, acute DVT and an indication to
receive anticoagulation for ≥3 months will be included.
If anticoagulation is administered for a shorter period
than planned, patients will remain in the study.
Study outcomes
Primary study outcomes are the incidence of treatment-
emergent adverse events, namely major bleeding,
symptomatic recurrent venous thromboembolic events
and all-cause mortality. Major bleeding is defined as
overt bleeding associated with a fall in haemoglobin
of ≥2 g/dl; or a transfusion of ≥2 units of packed red
blood cells or whole blood; or bleeding at a critical
site (intracranial, intraspinal, intraocular, pericardial,
intra-articular, intramuscular with compartment syndrome,
retroperitoneal); or death. Secondary outcomes include:
major cardiovascular events; patient-reported treatment
satisfaction and adherence; healthcare resource utilization;
reasons for drug switching or interruption of treatment;
and adverse events, including serious adverse events. Data
on patients with renal impairment treated for acute DVT
within the terms of the local product information will also
be collected and analysed. The Adjudication Committee,
blinded to the treatment group, will adjudicate bleeding
events; recurrent VTE and other thromboembolic events;
major cardiovascular events; and cause of death. Local
objective diagnosis of symptomatic recurrent venous
thromboembolic events is a prespecified criterion for
event adjudication.
Drug administration
The type, dose and duration of drug therapy are at
the sole discretion of the attending physician. Enrolment
will only be considered after the treatment decision
has been made. Patients who commence treatment
with rivaroxaban, or those who initially receive treatment
with heparin/fondaparinux within 48 hours of enrolment,
can be included in the rivaroxaban cohort. Patients in
the standard-of-care cohort are those receiving other
recommended pharmacological treatments for VTETable 2 Inclusion and exclusion criteria for XALIA
Inclusion Exclusion
● Female or male patients who
are ≥18 years of age
● Patients with acute
symptomatic PE*
● Diagnosis of acute DVT,
objectively confirmed
● Other exclusion criteria are
dependent on local product
information
● Indication for anticoagulation
therapy for at least 12 weeks
● Patients willing to participate in the
study and available for follow-up
*A parallel symptomatic PE is not an exclusion criterion; however, XALIA will
not enrol patients with only PE.
DVT, deep vein thrombosis; PE, pulmonary embolism.according to international guidelines, e.g. initial unfractio-
nated heparin, LMWH or fondaparinux, which may overlap
with and be followed by an oral VKA. However, in routine
clinical practice many patients for whom rivaroxaban is
planned may initially receive parenteral anticoagulants for a
period longer than 48 hours before they are switched to
rivaroxaban. These patients will be excluded from the main
analysis, but the allocation of these patients will be subject
to sensitivity tests as follows: 1) they will be analysed
separately and 2) they will be allocated to standard of
care or rivaroxaban dependent on the distribution of
days (after the first 48 hours) in which they actually
switched to rivaroxaban; the cut-off points that will
be used for these sensitivity analyses will be defined by the
quartiles of the distribution of days (after the 48 hours) in
which the switch occurs.
Concomitant medications taken prior to or during
the study will be documented and include non-steroidal
anti-inflammatory drugs, acetylsalicylic acid, clopidogrel,
steroids, medications known to interact with the DVT
treatment, and medications known to increase or reduce
the incidence of DVT (e.g. hormone therapy). Other drugs
will be recorded if considered medically relevant by
the investigator. Any changes to VTE treatment, including
switching or cessation of treatment, will be documented.
Data acquisition
All patient data will be collected during the initial visit
and routine follow-up visits (occurring around month 1,
quarterly and at final assessment) or by mail, telephone
or email (Table 3). Demographic data and clinical
characteristics will be collected from medical records
if available, or by patient interviews. Patient-reported
treatment satisfaction will be assessed using a specific
treatment satisfaction questionnaire: the validated
Anti-Clot Treatment Scale (ACTS), as used in the
EINSTEIN DVT and EINSTEIN PE studies [24,25].
Statistical analysis
The primary statistical analysis includes a descriptive
analysis of the primary and secondary outcomes. The
primary outcome variable is the incidence of treatment-
emergent adverse events, namely major bleeding and
symptomatic recurrent VTE. An adverse event is consid-
ered as treatment emergent if it starts on or after the
day of the first dose of study medication and ≤2 days
after the last dose. All patients who took at least one
dose of medication will be included in the safety popula-
tion. For primary and secondary variables, incidence
proportions and incidence rates will be estimated, to-
gether with 95% confidence intervals. The accepted
range for the 95% confidence intervals is estimated to
be between the allocation ratios of 1:3 and 3:1; there-
fore, at least 25% of patients at each study centre
Table 3 Overview of data collection procedures





Visit date X X X X
Demographic data X
Medical/surgical history X
Concomitant diseases X X* X*
Concomitant medication/treatment X X* X*
Physical examination X
Laboratory results (if available) X X X X
Diagnosis of current DVT X
Previous VTE X
Current VTE treatment regimen X X X
Initial phase treatment X
Dose reduction (twice daily to once daily) X
Assessment of therapy X
Patient satisfaction and adherence with treatment (optional, only in a sub-sample of patients) X* X* X*
Adverse events† X X X
*Only documented if new information is available from regular practice. No additional diagnostics are required for the study; †serious adverse events must be
reported to the sponsor within 24 hours.
DVT, deep vein thrombosis; VTE, venous thromboembolism.
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therapy. To compare the treatment arms, the risk dif-
ference and corresponding 95% confidence interval
will be calculated, and time-to-event analyses will be
conducted.
The potential for allocation bias in open-label, non-
randomized studies will be minimized by also present-
ing a propensity score analysis to control the effect of
unbalanced covariates [26,27]. To minimize selection
bias, physicians will be asked to document patients
consecutively. To decrease the possibility of reporting
bias, source data will be verified at approximately
10% of study centres in countries where this is legally
possible. A sample size of 4800 patients assumes that
17% of patients will be non-evaluable because of non-
overlapping propensity scores or because of withdrawn
informed consent forms.
Discussion
The demand for real-world data in addition to clinical
trial data is increasing. Non-interventional studies are
crucial for obtaining a different perspective on the safety
and effectiveness of drugs when used in routine clinical
practice. Unlike registry data, which is typically analysed
retrospectively, studies such as XALIA are designed to
assess prospectively defined outcomes of interest thus
eliminating potential bias. It is anticipated that XALIA
will provide important information on the treatment
of DVT in a heterogeneous patient population in a
real-world setting. Strict inclusion and exclusion criteriain randomized clinical trials, such as EINSTEIN DVT,
may restrict the population in which therapies can be
studied, and it is important to show that the findings from
clinical trials are applicable to patients treated in routine
clinical practice.
One challenge with open-label observational studies is
the potential for increased reporting of adverse events
with the new drug, otherwise known as the Weber effect
[28]. This may be a result of increased patient exposure
and higher interest in the drug; however, when physicians
become familiar with the drug and its adverse event
profile, the rate of reported adverse events usually declines
[28]. Therefore, it may be anticipated that this effect will
also occur with rivaroxaban, at least during the initial
period after its approval for the treatment of VTE.
Findings from XALIA may enable healthcare profes-
sionals to gain new insights into the management of
patients with DVT, particularly regarding the risks of
bleeding and recurrent VTE. Patients are at an imme-
diate and continued risk of recurrence after the first
venous thromboembolic event [29], and this risk can be
substantial after cessation of anticoagulation [30,31].
Real-world data on recurrence rates will, therefore, be
meaningful, particularly in patients who may discontinue
anticoagulation. In some cases, the optimal duration of
anticoagulation therapy for DVT is unclear; this may be
partly owing to challenges in maintaining an appropriate
benefit–risk balance because of an increased risk of bleed-
ing or a patient’s intrinsic risk factors [5]. It is hoped that
by evaluating the incidence and type of thromboembolic
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representation of the benefit–risk profile of rivaroxaban in
routine care will be provided.
The clinical impact of anticoagulant-related bleeding
complications is often severe. The case–fatality rate for
major bleeding in patients with VTE has been reported
to be as high as 11% within the first 3 months [32].
Furthermore, data from the RIETE registry showed
that 56% of deaths in patients with VTE who received
anticoagulation for 3 months were as a result of
bleeding [33]. As mentioned previously, clinical trials
are selective in nature, and may underestimate the
frequency of bleeding seen in clinical practice. Results
from a large community-based trial in the US showed
an annual incidence of major bleeding as high as 12–13%
in patients with VTE [34]. XALIA will provide valuable
information on the incidence of major bleeding events
that may occur with rivaroxaban or standard therapy in
patients with DVT.
Conclusions
XALIA is a large, non-interventional study investigating
the safety of rivaroxaban compared with standard of care
for the treatment of acute DVT in routine clinical practice.
Real-world data in a large cohort across multiple countries
will be a valuable addition to the results of the EINSTEIN
programme. The study was started in June 2012, will
complete recruitment in early 2014, and results are
expected in 2015.
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